Investment Rating - The report maintains a "Buy" rating for the company [7][3][8] Core Views - The company has completed the acquisition of 100% of the shares of a Singapore-based TCM clinic, marking the beginning of its overseas expansion [7][8] - The company plans to increase its store count in Singapore and expand into markets such as Hong Kong and Malaysia, with expected overseas revenue of 200-300 million RMB by 2026 [7][8] - The domestic policy environment is stabilizing, which is expected to benefit leading companies in the sector [7][8] - The management's confidence is reflected in significant share buybacks and a commitment to maintain a 50% dividend payout ratio [7][8] Financial Summary - Sales revenue is projected to grow from 3,022 million RMB in FY24 to 4,099 million RMB in FY26, representing a growth rate of 30.1% and 21.9% respectively [2][12] - Adjusted net profit is expected to increase from 400 million RMB in FY24 to 555 million RMB in FY26, with growth rates of 31.4% and 23.8% respectively [2][12] - The adjusted earnings per share (EPS) is forecasted to rise from 1.64 RMB in FY24 to 2.40 RMB in FY26 [2][12] Valuation - The target price is set at 44.95 HKD, with a potential upside of 50.3% from the current price of 29.90 HKD [3][7] - The adjusted price-to-earnings (PE) ratio for FY26 is estimated at 11.5x [7][10] Shareholder Structure - The largest shareholder holds 35.1% of the company, indicating a concentrated ownership structure [4]

Investment Rating - The report assigns a "Buy" rating to the company, indicating a positive outlook for investment [12]. Core Insights - The company is a leading player in the water supply industry, with steady growth in its core water supply business and a first-mover advantage in pipeline drinking water [4][7]. - By FY2025, the company's urban water supply business will serve over 30 million people, while its pipeline drinking water business will serve approximately 12 million [4][7]. - The company has reached a turning point in free cash flow, with expectations for increased dividends in the future [4][11]. Summary by Sections Company Overview - The company operates primarily in urban water supply and pipeline drinking water, with a diversified revenue structure [19][21]. - As of FY2025, the revenue breakdown includes urban water supply (64.3%), environmental protection (13.1%), and other segments [24]. Financial Highlights - The company’s capital expenditure peaked at HKD 51.4 billion in FY2024, decreasing to HKD 32.4 billion in FY2025, leading to a positive free cash flow of HKD 1.50 billion [8][32]. - The dividend payout ratio for FY2025 is projected to be 42.53%, with potential for future increases as free cash flow improves [32]. Water Sector Analysis - The urban water supply and sewage treatment sectors are experiencing stable growth, with a projected CAGR of 0.37% for water supply and 1.2% for sewage treatment from 2025 to 2027 [9][40]. - The company’s operational capacity as of FY2025 includes 730,000 tons/day for water supply and 90,000 tons/day for sewage treatment, with ongoing projects across various provinces [47][49]. Strategic Positioning - The company primarily operates under the Transfer-Own-Operate (TOO) model, which enhances its asset value compared to other models [51]. - The company is expected to benefit from the current round of price adjustments in the water supply sector, with recent increases in basic water prices averaging 21.3% [52].

Investment Rating - The report does not explicitly state an investment rating for Yue Yuen International, but it provides insights into the company's performance and management expectations for future quarters [1][7]. Core Insights - Yue Yuen International reported a revenue of USD 6.02 billion for 9M25, a decrease of 1.0% year-on-year, and a net profit of USD 279 million, down 16% year-on-year. For 3Q25, revenue was USD 1.96 billion, down 5% year-on-year, marking the third consecutive quarter of sequential decline, with a net profit of USD 110 million, down 27% year-on-year [1][7]. - The management maintains a prudent dividend policy with a payout ratio of around 70% [1][7]. - The manufacturing segment faced pressure on footwear shipment volumes, but an increase in average selling price (ASP) partially offset revenue declines. The ASP for 3Q25 rose by 3.4% year-on-year to USD 21.4 per pair [2][8]. - Management expects retail performance to improve in 4Q25, with continued increases in ASP and gross margin [2][8]. Summary by Sections Manufacturing Business - In 3Q25, manufacturing revenue was USD 1.96 billion, down 4.5% year-on-year, with footwear manufacturing revenue at USD 1.35 billion, down 2% year-on-year. Footwear shipment volume was approximately 63 million pairs, down 5.3% year-on-year [2][8]. - The gross margin for manufacturing in 3Q25 was 19.4%, up 1.6 percentage points quarter-on-quarter but down 1.2 percentage points year-on-year, primarily due to uneven capacity loading and lower utilization rates [2][8]. - Management indicated that current order visibility is about 2-3 months, with some brands showing resilient demand for 1Q26 [2][8]. Retail Business - Pou Sheng recorded revenue of approximately RMB 3.74 billion in 3Q25, down 6.3% year-on-year, with a gross margin of 33.4% [3][9]. - The company is optimizing its offline network, reducing the number of self-operated stores to 3,338 as of September 2025, a decline of about 28% compared to the end of 2021 [3][9]. - Management expects the 4Q performance to improve, with a focus on new product launches and a lower discounting environment [3][9]. Future Outlook - Management views Indonesia and India as key markets for medium- to long-term expansion, anticipating improvements in manufacturing gross margins starting in 2026 [4][10]. - The overall industry is currently at a trough, with expectations for recovery in 2027 as the company continues to optimize its operations and seize opportunities in lower-tier markets [4][12].

Investment Rating - The report maintains a "Buy" rating for the company [6] Core Insights - The company's profitability continues to improve, with exports expected to become a new growth driver [2] - EPS forecasts for 2025-2027 are adjusted to 1.68, 2.04, and 2.40 RMB respectively, with a target price set at 22.44 RMB and 24.62 HKD, based on a PE ratio of 11 times for comparable companies in 2026 [3] Financial Performance Summary - Revenue (in million RMB) is projected to grow from 179,204 in 2023 to 448,685 in 2027, with year-on-year growth rates of 21.1%, 34.0%, 33.0%, 21.3%, and 15.8% respectively [5] - Operating profit (in million RMB) is expected to increase from 3,806 in 2023 to 23,173 in 2027, with significant growth rates of 4.3%, 100.8%, 110.0%, 22.2%, and 18.1% [5] - Net profit attributable to the parent company (in million RMB) is forecasted to rise from 5,308 in 2023 to 24,318 in 2027, with growth rates of 0.9%, 213.3%, 2.5%, 20.9%, and 18.0% [5] - The gross margin is projected to improve from 15.3% in 2023 to 17.3% in 2027, while the net margin is expected to stabilize around 5.3% [5] Market Position and Strategy - The company is expected to maintain a strong market share, with sales growth outpacing the industry average, particularly in the electric vehicle segment [10] - The company is accelerating its global expansion, with exports anticipated to become a significant source of revenue and profit growth [10]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Insights - The company achieved a quarterly revenue of 19.45 billion yuan in Q3 2025, representing a year-on-year increase of 97.3% and a quarter-on-quarter increase of 36.7% [7] - The company reported a net profit attributable to equity holders of 150 million yuan in Q3 2025, a significant improvement from a loss of 690 million yuan in Q3 2024 and a profit of 160 million yuan in Q2 2025 [7] - The company’s Q3 sales volume reached 174,000 units, with a year-on-year increase of 107.3% and a quarter-on-quarter increase of 29.6% [7] - The average selling price (ASP) for the company was 112,000 yuan, showing a year-on-year decrease of 4.8% but a quarter-on-quarter increase of 5.4% [7] - The gross margin for Q3 was 14.5%, reflecting a year-on-year increase of 6.4 percentage points and a quarter-on-quarter increase of 0.9 percentage points [7] - The company’s sales, management, and R&D expense ratios improved to 4.9%, 3.2%, and 6.2% respectively, compared to the previous year [7] - The company has expanded its sales service network to cover 292 cities with 866 sales outlets as of the end of September 2025 [7] - The company exported 17,000 vehicles in Q3 2025, a quarter-on-quarter increase of 36% [7] - The company plans to launch its Lafa5 model overseas in Q2 2026 and is actively pursuing local production capabilities in Malaysia and Europe [7] Financial Projections - The total revenue forecast for the company is projected to reach 65.8 billion yuan in 2025, with a year-on-year growth of 104.58% [1] - The net profit attributable to the parent company is expected to be 693.83 million yuan in 2025, with a significant year-on-year increase of 124.60% [1] - The earnings per share (EPS) is projected to be 0.49 yuan in 2025, with a P/E ratio of 103.14 [1] - The company’s gross margin is expected to improve to 15% in 2025 [8] - The company’s asset-liability ratio is projected to be 77.45% in 2025 [8]

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 12.00 [3][5]. Core Insights - The company is focusing on research and development of large models, AI-native software, and AI intelligence as its core development direction. The management expects cloud services to maintain a revenue growth of 20% annually, while overall core business revenue is projected to grow by 15% annually [3]. - The company has introduced a new software product, "浪潮海岳 inSuite by DELMIAWorks," aimed at the discrete manufacturing industry, which integrates various core business functions for digital transformation [2]. - The company plans to expand its overseas enterprise service market, starting with SaaS services for Southeast Asian companies next year, which is expected to become a second growth curve for the company [3]. Financial Summary - For FY25E, the net profit is projected to be RMB 522 million, representing a year-on-year increase of 35.6%, and for FY26E, it is expected to reach RMB 624 million, a 19.5% increase. The compound annual growth rate (CAGR) for net profit from FY25E to FY27E is estimated at 19.1% [3][4]. - The company’s revenue for FY23 was RMB 8,294 million, with a growth rate of 19.1%. For FY24, revenue is expected to decrease slightly to RMB 8,201 million, followed by a recovery to RMB 8,758 million in FY25 [4][8]. - The diluted earnings per share (EPS) for FY25E is projected at RMB 0.457, increasing to RMB 0.546 in FY26E and RMB 0.648 in FY27E [4][8].

Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [2][12]. Core Insights - The company has shown strong revenue growth in FY26H1, with a total revenue of 4.047 billion RMB, representing a year-over-year increase of 32.7% and a half-year increase of 10.8% [5]. - The company is positioned as a leader in the domestic offline ticketing market, with significant IP licensing capabilities, including partnerships with major brands like Sanrio and Chiikawa [12]. - The report highlights the robust growth potential in the live performance and IP sectors, driven by a stable supply of top-tier artists and successful events [6][12]. Financial Performance Summary - **Revenue and Profitability**: In FY26H1, the company achieved a gross profit margin of 35.7%, with a net profit of 520 million RMB, reflecting a year-over-year increase of 54.3% [5]. - **Segment Performance**: The live performance and technology segment generated 1.339 billion RMB in revenue, up 14.5% year-over-year, while the IP derivatives segment saw a remarkable 105.2% increase in revenue, reaching 1.16 billion RMB [6][7]. - **Cost Management**: The company has effectively reduced both sales and management expenses, leading to improved operational efficiency [10]. Future Projections - The company is projected to achieve revenues of 8.107 billion RMB in FY2026, with a net profit forecast of 996 million RMB, indicating a significant growth trajectory [11][12]. - The expected growth rates for revenue and net profit are 21% and 174% respectively for FY2026, showcasing strong financial health and operational performance [12][13].

Investment Rating - The report maintains an OUTPERFORM rating for Geely Automobile Holdings with a target price of HK$26.60 [2][4][15]. Core Insights - The company is expected to achieve vehicle deliveries of 3.04 million, 3.52 million, and 3.97 million units for 2025, 2026, and 2027 respectively, with NEV penetration rates projected at 57%, 59%, and 66% [4][15]. - The report anticipates a core net profit attributable to shareholders of Rmb16.40 billion, Rmb18.88 billion, and Rmb22.45 billion for 2025, 2026, and 2027, reflecting a growth rate of -1%, 15%, and 19% respectively [4][15]. - The company is expected to fully realize synergies from its consolidation with ZEEKR by 2026, enhancing profitability and operational efficiency [6][18]. Financial Performance - In Q3 2025, Geely reported revenue of Rmb89.19 billion, a 27% year-on-year increase, while cumulative revenue for the first nine months reached Rmb239.48 billion, up 26% year-on-year [5][16]. - The core net profit for Q3 2025 was Rmb3.96 billion, a 19% increase year-on-year, with a total of Rmb10.62 billion for the first nine months, marking a 59% year-on-year growth [6][17]. - The company maintained a strong cash position with Rmb56.22 billion in cash at the end of September 2025, representing a 31% year-on-year increase [5][16]. Market Position and Strategy - Geely is positioned to achieve its 2025 sales target comfortably, with expectations of 3.04 million units sold, while ZEEKR's overseas sales are projected to grow by 50% to 80% [18][19]. - The report highlights that the company retains strategic advantages in NEV rollout, export expansion, and brand-mix upgrading, which are expected to support continued market share gains in a moderately growing industry [19].

Investment Rating - The report initiates coverage with a "Buy" rating for Jacobiopharma-B (1167.HK) [1]. Core Views - Jacobiopharma focuses on innovative drug development targeting difficult-to-drug targets, with a strong pipeline and comprehensive patent strategy to build competitive barriers [6][7]. - The company has established strategic partnerships to enhance drug development and commercialization, particularly with AbbVie and Elysium [6][20]. - The KRAS G12C inhibitor, Goleirase, has been approved for marketing in China, and the company is actively pursuing further clinical trials and partnerships to maximize its market potential [6][39]. Summary by Sections 1. Focus on Difficult-to-Drug Targets - Jacobiopharma aims to develop globally innovative drugs targeting difficult-to-drug cancer targets, with a management team experienced in drug development and international collaboration [13][17]. - The company's revenue primarily comes from licensing agreements, with stable funding supporting long-term development [20][24]. - The company has a solid cash position of 1.34 billion yuan as of June 30, 2025, which supports its future expenditures [20][24]. 2. Coverage of Different KRAS Mutations - KRAS plays a critical role in cell growth and survival signaling, and its mutations are linked to cancer progression [30]. - The KRAS G12C inhibitor, Goleirase, has been approved in China, and the company has formed a strategic partnership with Elysium for its commercialization [36][39]. - The company is also developing a pan-KRAS inhibitor, JAB-23E73, which is expected to provide broader coverage of KRAS mutations and address resistance issues [46]. 3. Key Assumptions and Investment Rating - The report projects revenues of 0.52 billion yuan in 2025, 0.74 billion yuan in 2026, and 1.15 billion yuan in 2027, reflecting the company's growth trajectory [8][12]. - The company is expected to continue advancing its research and development projects while maintaining controlled operating expenses [6][20].

Investment Rating - The report maintains a "Buy" rating for JD Health (06618) [4][10] Core Insights - JD Health's Q3 2025 financial results exceeded expectations, with revenue of 17.12 billion (up 28.7%) and adjusted net profit of 1.90 billion (up 42.4%) [8][9] - The company is expected to benefit from strong growth in drug sales, increased advertising revenue, and enhanced AI capabilities [9][10] - The report projects revenue growth for 2025-2027, with estimates of 70.95 billion, 81.99 billion, and 93.49 billion respectively [6][10] Financial Data and Profit Forecast - Revenue and profit forecasts for JD Health are as follows: - 2023: Revenue 53.53 billion, Net Profit 2.14 billion - 2024: Revenue 58.16 billion, Net Profit 4.16 billion - 2025E: Revenue 70.95 billion, Net Profit 4.74 billion - 2026E: Revenue 81.99 billion, Net Profit 5.66 billion - 2027E: Revenue 93.49 billion, Net Profit 6.76 billion [6][12]